Eric Verdin, MD, is the president and CEO of the Buck Institute for Research on Aging; a professor at the Leonard Davis School of Gerontology at the University of Southern California; and a professor at the University of California, San Francisco.
Dr. Verdin discusses several breakthroughs, including:
How we can change our own personal rate of aging
Rapamycin as an example of a modulator of aging rate
Aging is the largest risk factor for non-communicable diseases
The need for healthcare to be reinvented as proactive care, not just sick care
The relative unimportance of our genetics to how well we age
I think Dr. Verdin is pointing the Buck Institute in the right direction, studying interventions that can be used soon or now to extend healthspan and lifespan. I donât agree with all of this diet advice, but thatâs par for the course. In general, he gives solid, mainstream advice while the Buck does more cutting edge research.
I missed that the first time. Thanks. Is he referring to ânumber needed to treatâ?
In my interview with Nathan Price (now of Thorne), he said variability in gut microbiome affected the effectiveness of statins. That said, donât cardiologists look at apoB or LDL to see if the statin is working?
Does anyone know what study (âwe knowâ) Verdin is referring to?
A very interesting YouTube video in case you missed it. This is the first time I have seen a company trying to commercialize an anti-aging strategy and provide it to everyone at the lowest possible cost. Their product is in phase 1&2 trials. Their main theory if I got it right is modulation of the immune system is the key to longevity. I hope their trial succeeds and they get their product to market as soon as possible at an affordable price.
In the meantime, we have rapamycin as an immune system modulator.
Thanks for finding this. This is great. Interesting that Peter Diamandis is connected to the company. Sounds like a really interesting product. Agreed, I hope the trial succeeds and they can get it to the masses quickly.
On average we get about 1 âmiracleâ drug per decade that lowers mortality from a specific cause and also has a trend to decreased acm (sometimes even statistically significantly so).
âBased on available information, Immunis treatment costs are extremely high, exceeding $100,000 per patient. This is due to the complex manufacturing process, which takes over three weeks to complete, resulting in a high processing cost of around $60,000 per patient. Additionally, pharmaceutical companies justify these costs by highlighting the value of Immunis drugs and continued investment in research and development.â
âNote: These figures are based on available data and may vary depending on individual circumstances and insurance plans.â
I donât think this is correct. I canât find the talk, but Hans Keirstand has specifically said that theyâve already scaled this and the final product will be very affordable. Heâs mentioned it several times. That said, once big Pharma gets hold of it, theyâll be charging us out the ass.
Yes, I heard the same presentation{which is not the one post]. In that same video I recall him saying it was available outside the US.
As I stated it was a basics simple search using an AI search engine.
If the clinic if FL that offer âhyperbaric oxygen treatmentâ charges if I recall $60K for a series of treatment.
Exosomes{produced from human umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs)] are the the $1000 to $3000 per vile range{this is just for the material] depending on the amount of Exosomes. Plus the fee / cost of consultation and injection.
I do not see this as being an âaffordableâ treatment for the general public/average person.
What do you consider âaffordableâ for the general public,?
My understanding is that Immunis is not available anywhere. Itâs currently in phase 2a trials and is not for sale. Maybe weâre talking about a different thing? Aviv clinics run HBOT treatments out of Florida. but I donât believe thereâs a connection.
